Status:
COMPLETED
Relationship Between Sleep Apnea Syndrome and Patent Foramen Ovale Among Victims of Cryptogenic Ischemic Stroke
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Apnea Syndrome
Stroke
Eligibility:
All Genders
18-60 years
Brief Summary
Obstructive sleep apnea syndrome (OSAS) and patent foramen ovale (FOP) are considered as risk factors for stroke. OSAS generates a pressure increase in the right cavity during inspiratory efforts, whi...
Detailed Description
Obstructive sleep apnea syndrome (OSAS) and patent foramen ovale (PFO) are considered as risk factors for stroke. In most cases, the presence of FOP has no clinical impact. Certain hemodynamic conditi...
Eligibility Criteria
Inclusion
- \- Patients who have had a cerebral or retinal infarction confirmed by brain imaging or a defined transient ischemic attack without an identifiable cause after a detailed etiological assessment
Exclusion
- Identification of a cause of ischemic stroke:
- Atheromatous stenosis \> 50% (or atherosclerotic plaque \< 50% threatening) of supra aortic trunk or intracranial arteries on echodoppler of the supra aortic trunk and transcranial or scanner angiography.
- Emboligenic heart disease : atrial fibrillation and atrial flutter, thrombus in left atrium, spontaneous contrast in left atrium, decreased atrial flow, left ventricular ejection fraction (LVEF) \< 40%, LV aneurysma, left intraventricular thrombus, recent myocardial infarction, cardiomyopathy ventricular dilated left with LVEF \< 35%, mitral stenosis, prosthetic mitral or aortic valve, infectious and non-infectious endocarditis, valve or mural tumor, complicated aortic arch atheroma (plaque \> = 4 mm, ulcerated plaque, thrombus on plaque), aortic dissection
- Lacunar infarction symptomatic = \< 1.5 cm on the CT scan, = \< 2 cm on the diffusion MRI or the FLAIR.
- No atherosclerotic arteriopathy : dissection, primary and secondary angitis, spastic angiopathy, etc…
- Coagulopathy to come a long-term anticoagulant treatment (\> 6 months) (anti-phospholipid syndrome, thrombophilia).
- Blood disorders and cancer
- Recent intravenous drug use (in the 6 months before the stroke).
- Other potential causes:
- Severe respiratory impairment or pulmonary arterial hypertension
Key Trial Info
Start Date :
March 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT04846205
Start Date
March 24 2021
End Date
September 30 2021
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055